Tango Therapeutics, Inc.
A clinical-stage biotechnology company developing precision cancer medicines, Tango Therapeutics uses a CRISPR-based platform to find genetic "weak spots" in tumor cells and build drugs that attack them. Founded in 2017 in the Boston area, the company takes its name from "synthetic lethality," a biological tango where two gene flaws together kill a cell, while either alone does not. Its lead drug candidate, vopimetostat, is being tested against pancreatic cancer.
Bought 1.25M · Sold 225.0K
Sold 4.59M
Sold 5.98M
Sold 2.70M
Granted 230.6K · Sold 58.4K
Sold 584.7K
Granted 362.5K
Granted 109.9K · Sold 22.3K
Granted 278.5K · Sold 254.7K
Granted 50.2K · Sold 8.1K
Granted 16.5K · Bought 20.0K
Granted 40.0K
Granted 24.9K
Granted 22.9K
Granted 12.5K
Granted 16.5K · Sold 5.0K
Granted 5.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Boxer Asset Management Inc. +4 co-filersSee remarks · 4 transactions | — | 30.06Mas of Oct 2023 | — | 1.25M | 225.0K |
| Davis Aaron I. +1 co-filerSee remarks · 4 transactions | — | 17.51Mas of Nov 2024 | — | — | 4.59M |
| TRV GP IV, LLC +2 co-filers10% owner · 24 transactions | -30.9% | 13.39M | — | — | 5.98M |
| EcoR1 Capital, LLC10% owner · 3 transactions | — | 10.63Mas of Nov 2024 | — | — | 2.70M |
| Weber BarbaraDirector, Executive Chair, Director · 9 transactions | +11.8% | 1.63M | 230.6K | — | 58.4K |
| Davis Aaron I. +1 co-filerSee remarks · 8 transactions | — | 597.3Kas of Jul 2024 | — | — | 584.7K |
| Peters MaltePresident & CEO, Director · 3 transactions | +7250% | 367.5K | 362.5K | — | — |
| Beckman DaniellaChief Financial Officer · 9 transactions | +90.6% | 184.3K | 109.9K | — | 22.3K |
| Crystal AdamPresident, R&D · 24 transactions | +68.1% | 136.6K | 278.5K | — | 254.7K |
| Barry DouglasGeneral Counsel · 6 transactions | +176.2% | 66.0Kas of Feb 2025 | 50.2K | — | 8.1K |
| Rothenberg MaceDirector · 5 transactions | +730% | 41.5K | 16.5K | 20.0K | — |
| Gall MatthewChief Financial Officer · 1 transaction | — | 40.0K | 40.0K | — | — |
| Ketchum John BDirector · 4 transactions | — | 24.9K | 24.9K | — | — |
| Lee SungDirector · 3 transactions | — | 22.9K | 22.9K | — | — |
| Borisy AlexisDirector · 2 transactions | +250% | 17.5Kas of Jun 2025 | 12.5K | — | — |
| Calhoun Lesley AnnDirector · 4 transactions | +230% | 16.5K | 16.5K | — | 5.0K |
| Azelby RobertDirector · 1 transaction | — | 5.7K | 5.7K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -13.15M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.